BioWorld

Aug. 2, 2007

View Archived Issues

Hana Licenses Zensana To Par, Focuses On Oncology Pipeline

Hana Biosciences Inc., which earlier this year withdrew a new drug application filing for the antiemetic agent Zensana, licensed the product to Par Pharmaceutical Cos. Inc. (BioWorld Today) Read More

Advisory Panel: Thumbs Up To Tysabri For Limited Use In CD

Read More

Better Magnetic Nanoparticle May Enable Virus-Free Gene Therapy

Read More

Diagnostic Lab Firm Genoptix Files for $86.25 Million IPO

Read More

Clinic Roundup

Read More

Other News To Note

Read More

Appointments And Advancements

Read More